In this systematic review and meta-analysis of head-to-head comparative effectiveness studies involving patients with IMIDs treated with JAK inhibitors or TNF antagonists, we observed no meaningful differences in the risk of serious infections, malignant neoplasms, MACEs, or VTE, with a low incidence of serious adverse events. Here, TNF is linked to cancer.